Skip to main content
HLB Therapeutics Co.,Ltd. logo

HLB Therapeutics Co.,Ltd. — Investor Relations & Filings

Ticker · 115450 ISIN · KR7115450009 KO Manufacturing
Open in API
Filings indexed 444 across all filing types
Latest filing 2022-03-11 Proxy Solicitation & In…
Country KR South Korea
Listing KO 115450

About HLB Therapeutics Co.,Ltd.

https://hlbtherapeutics.co.kr/en/

HLB Therapeutics Co., Ltd. is a biopharmaceutical company specializing in the development of innovative, first-in-class drugs for rare and intractable diseases. The company's clinical-stage pipeline focuses on addressing unmet medical needs in ophthalmology and oncology. Key development programs include RGN-259, a therapeutic agent for Dry Eye Disease and Neurotrophic Keratopathy, and OKN-007 for the treatment of Glioblastoma Multiforme. Additionally, the company is advancing a Natural Killer (NK) cell therapy through late-stage clinical trials to provide new therapeutic options for patients.

Recent filings

Filing Released Lang Actions
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Proxy Solicitation Reference Document) and contains information regarding the solicitation of proxies for the 22nd Annual General Meeting of Shareholders of HLB Therapeutics. It includes details on the meeting date, agenda items (approval of financial statements, director/auditor compensation), and instructions for electronic voting. While it contains financial statements, these are provided as part of the proxy solicitation materials for shareholder review prior to the meeting, not as a standalone annual report or financial filing. Therefore, it is classified as a Proxy Solicitation & Information Statement.
2022-03-11 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of General Meeting of Shareholders' (주주총회소집공고) for HLB Therapeutics. It includes the meeting date, location, agenda items (such as approval of financial statements and director remuneration), and information regarding electronic voting. This document is a standard proxy solicitation and meeting notice provided to shareholders, which falls under the 'Proxy Solicitation & Information Statement' category.
2022-03-11 Korean
기타시장안내(약명및영문명)(한글약명)
Regulatory Filings Classification · 95% confidence The document is a short notice regarding a change in the company's stock name (abbreviation) on the exchange. It does not fit into specific categories like financial reports, dividends, or director dealings. As it is a miscellaneous regulatory announcement regarding market listing details, it falls under the RNS category.
2022-01-11 Korean
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding a 'Capital Increase Decision' (유상증자결정) for the company GTreeBNT. It details the issuance of new shares, the purpose of the capital raise, the third-party allocation details, and the schedule for listing. This falls under the category of announcements regarding new share issues and capital structure changes.
2022-01-03 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the acquisition of significant shareholding interests (specifically call options on convertible bonds) by 'Nomad No. 1 Association' and its special related parties in 'HLB Therapeutics'. This falls under the category of Major Shareholding Notification.
2021-12-30 Korean
타법인주식및출자증권취득결정(자율공시)
M&A Activity Classification · 95% confidence The document is a formal regulatory filing from HLB Therapeutics regarding the acquisition of shares/equity in another entity (Nomad Fund No. 2). It details the acquisition amount, purpose, and board approval, which is a standard corporate disclosure for M&A or investment activity. Since it does not fit into specific categories like 'TAR' (which usually implies larger M&A/takeover bids) or 'SHA' (capital changes), and it is a specific regulatory disclosure of an investment decision, it falls under the 'RNS' (Regulatory Filings) category as a general corporate announcement.
2021-12-27 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.